Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ritter Pharmac. Com (RTTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,383
  • Shares Outstanding, K 5,730
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,860 K
  • 36-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.09
  • Number of Estimates 1
  • High Estimate -1.09
  • Low Estimate -1.09
  • Prior Year -1.10
  • Growth Rate Est. (year over year) +0.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.71 +11.27%
on 11/26/18
0.95 -16.84%
on 12/04/18
-0.07 (-8.14%)
since 11/14/18
3-Month
0.71 +11.27%
on 11/26/18
2.56 -69.14%
on 10/08/18
-0.88 (-52.69%)
since 09/14/18
52-Week
0.71 +11.27%
on 11/26/18
4.00 -80.25%
on 06/04/18
-2.13 (-72.95%)
since 12/14/17

Most Recent Stories

More News
Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019

RTTR : 0.79 (+3.27%)
Consolidated Research: 2018 Summary Expectations for E*TRADE Financial, Ballantyne Strong, Lincoln Educational Services, Electro-Sensors, Capital Southwest, and Ritter Pharmaceuticals -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of E*TRADE Financial Corporation...

LINC : 2.49 (+7.79%)
CSWC : 20.08 (-0.69%)
RTTR : 0.79 (+3.27%)
ELSE : 3.47 (-3.34%)
ETFC : 43.55 (-1.60%)
BTN : 2.15 (+3.86%)
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with...

RTTR : 0.79 (+3.27%)
Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI)...

RTTR : 0.79 (+3.27%)
Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases...

RTTR : 0.79 (+3.27%)
Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with...

RTTR : 0.79 (+3.27%)
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split

Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with...

RTTR : 0.79 (+3.27%)
Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with...

RTTR : 0.79 (+3.27%)
Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutics that modulate the gut microbiome to treat gastrointestinal diseases with an initial...

RTTR : 0.79 (+3.27%)
Technical Perspectives on Biotech Stocks -- PTC Therapeutics, Regeneron Pharma, Ritter Pharma, and Sangamo Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on PTCT, REGN, RTTR, and SGMO which can be accessed for free by signing up to www.wallstequities.com/registration....

PTCT : 33.63 (-0.39%)
SGMO : 11.48 (-0.78%)
RTTR : 0.79 (+3.27%)
REGN : 381.17 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade RTTR with:

Business Summary

Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance....

See More

Key Turning Points

2nd Resistance Point 0.82
1st Resistance Point 0.81
Last Price 0.79
1st Support Level 0.77
2nd Support Level 0.74

See More

52-Week High 4.00
Fibonacci 61.8% 2.74
Fibonacci 50% 2.36
Fibonacci 38.2% 1.97
Last Price 0.79
52-Week Low 0.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar